Humacyte, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 36.97 million compared to USD 19.83 million a year ago. Basic loss per share from continuing operations was USD 0.36 compared to USD 0.19 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.79 USD | +4.01% | +1.72% | +170.77% |
10/05 | Transcript : Humacyte, Inc., Q1 2024 Earnings Call, May 10, 2024 | |
28/03 | Transcript : Humacyte, Inc. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+170.77% | 892M | |
+46.49% | 58.71B | |
-3.33% | 41.31B | |
+36.42% | 39.2B | |
-11.22% | 27.4B | |
+9.70% | 26.55B | |
-22.26% | 18.98B | |
+1.15% | 12.51B | |
+25.87% | 12.08B | |
+21.08% | 11.94B |
- Stock Market
- Equities
- HUMA Stock
- News Humacyte, Inc.
- Humacyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023